Abstract: The invention provides methods of selecting polynucleotides based on their size in globular form. The polynucleotides may be treated with a condensation medium. e.g. comprising polyethylene glycol. e.g. PEG8000, and salt, in order to adopt a globular form. The method may employing filtering in order to retain the larger nucleic acids and make the larger nucleic acids available for sequencing applications, such as nanopore sequencing. The invention also relates to kits for selecting polynucleotides.

Abstract: Described herein, inter alia, are immunophilin binding compounds and methods of heating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.

Abstract: The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the macromolecule-supported compounds through a linker or linking moiety. The application further provides compositions comprising the macromolecule-supported compounds, as well as methods of treating cancer with the macromolecule-supported compounds.

Abstract: The present invention provides complexes of a specialized pro-resolving mediator (SPM), or a salt, ester, or amide thereof, and a cyclodextrin (CD), wherein the SPM is a hydroxylated, polyunsaturated fatty acid derived from arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, or docosapentaenoic acid, 20 or 22 carbon atoms in length, with 4, 5 or 6 conjugated double bonds arranged in diene, triene, or tetraene systems or combinations thereof; and related compositions and methods.

Abstract: Described herein, inter alia, are immunophilin binding compounds and methods of treating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.

Abstract: Disclosed are methods and compositions comprising glycopeptides obtained from gastrointestinal sources that have superior microbiota effects. Such compositions are advantageous for food stuff, including infant formulations.

Abstract: Saponin extracts containing at least 88% QS-21 main peak and >3% to 10% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects.

Abstract: Deuterium-labeled 4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)piperidines substituted with pyrrolo[3,4-b]pyridin-5-one, furo[3,4-b]pyridin-5(7H)-one, or [1,2,4]triazolo[4,3-a]pyrimidin-3(2H)-one are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.

Abstract: Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).

Abstract: Compounds of the Formula(I) wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and to the use of the compounds or compositions 10 in agriculture or horticulture for combating, preventing or controlling animal pests, including arthropods and in particular insects, moluscs, nematodes or representatives of the order Acarina.

Abstract: The present invention generally relates to controlled release of tetracycline antibiotics. Specifically, it relates to a complex comprising a tetracycline compound (TC) or a pharmaceutically acceptable salt, hydrate or solvate thereof and a divalent metal carboxylate; a pharmaceutical preparation comprising the complex, methods for manufacturing the complex and the pharmaceutical preparation, and a complex or a pharmaceutical preparation for use in a method for treatment of the human or animal body, in particular for therapy and/or prophylaxis of a bacterial infection; and/or wherein antibiotic activity is maintained over a prolonged period of time; and/or for the therapy and/or prophylaxis of an acute, chronic or recurrent periodontal disease.

Abstract: A method for at least partial deacetylation of a biopolymer comprising acetyl groups, including: a1) providing a biopolymer including acetyl groups; a2) reacting the biopolymer including acetyl groups with hydroxylamine (NH2OH) or a salt thereof at a temperature of 100° C. or less for 2-200 hours to form an at least partially deacetylated biopolymer; and a3) recovering the at least partially deacetylated biopolymer.

Abstract: Provided herein are compositions, devices, systems and methods for electrochemical synthesis. Further provided are devices comprising addressable electrodes controlling polynucleotide synthesis (deprotection, extension, or cleavage, etc.) The compositions, devices, systems and methods described herein provide improved synthesis, storage, density, and retrieval of biomolecule-based information.

Abstract: A ?-glucan composition and use thereof. Specifically provided are uses of the ?-glucan composition in preparing a composition for improving or treating immune-related diseases, said ?-glucan being a ?-glucan containing ?-1,3 and ?-1,6 glucosidic bonds in the molecules thereof, and having a molecular weight of 1-50 kDa. The ?-glucan features a novel structure, a controllable mass, abundant sources, simple preparation processing, high product purity, strong biological activity, and is easy to produce industrially, among other strengths. The resulting water soluble ?-glucan composition features better antitumor activity, has the potential to be developed into a safe and effective novel drug for improving or treating immune-related diseases and fighting tumors.

Abstract: Provided is a modified cellulose, a preparation method and application thereof. The modified cellulose includes a flame retardant cellulose ester film, and the preparation method includes: obtaining a homogeneous cellulose solution by adding a cellulose to an ionic liquid cosolvent system; obtaining a cellulose phosphite ester solution by adding dimethyl phosphite and a catalyst to the homogeneous cellulose solution for performing a transesterification; obtaining cellulose phosphite ester powder by regeneration solvent precipitation, washing, centrifugation, and drying of the cellulose phosphite ester solution; and obtaining the flame retardant cellulose ester film by evaporating solvent after dissolving the cellulose phosphite ester powder in dimethyl sulfoxide.

Abstract: The present invention relates to ophthalmic formulations wherein a synergistic combination of three different classes of disinfectants (a multimeric biguanide compound, a quaternary ammonium compound and an antifungal/anti-acanthamoeba compound, in particular a combination of polyhexamethylene biguanide, Polyquaternium-1 and myristamidopropyl dimethylamine) enables the use of high concentrations of hyaluronate for providing better comfort and support of corneal health without compromising antimicrobial efficacy. The novel ophthalmic formulations support the use of more than 7.5 times higher concentrations of hyaluronate than are present in currently marketed multi-purpose disinfection solutions.

Abstract: The present invention relates to acetyl glucosamine. In particular, the present invention relates to the use of acetyl glucosamine to improve cognition.

Abstract: Disclosed herein are pharmaceutical compositions for the treatment of neurologic disorders comprising an effective amount of one or more mTOR inhibitors and/or one or more BDNF inducers and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating or preventing neurologic disorders comprising administering an effective amount of a pharmaceutical composition comprising one or more mTOR inhibitors and/or one or more BDNF inducers and optionally an effective amount of one or more thyroid hormones.

Abstract: The present disclosure relates to solid state forms of ripretinib, processes for preparation thereof, as well as a pharmaceutical composition including the same.

Abstract: The present disclosure is directed to novel lipidated poly(amino acid)s (LPAAs). The present disclosure is further related to processes for preparing such novel lipidated poly(amino acid)s (LPAAs) and for preparing novel lipidated poly(amino acid)s nanoparticles (LPAANPs). Additionally, the present disclosure relates to processes for utilizing lipidated poly(amino acid)s (LPAAs) that are biocompatible and capable of drug delivery.